Speakers & agenda

Oxford Symposia - 4th Annual

OLIGO 2018 OXFORD:

Antisense & Therapeutic Nucleic Acids

10 April 2018, St Edmund Hall, Oxford, UK

Twitter: @LPMHealthcare, #OligoOx18

Speakers & agenda

(subject to change)

Tuesday 10th April 2018 | The Jarvis Doctorow Hall | St Edmund Hall | Oxford, UK


0830: Registration and coffee


0900: Welcome/housekeeping


0915: Professor Tom Brown, University of Oxford, Oxford, UK

Studies on Oligonucleotides with Chemically Modified backbones


0945: Dr Nebojsa Janjic, SomaLogic Inc, Boulder, CO, USA

Base modifications play a key role in folding and binding of DNA aptamers to proteins


1015: Professor Rula Zain, Karolinska University Hospital, Karolinska Institutet, Sweden

Disruption of non-B-DNA structures in triplet-repeat diseases using modified oligonucleotides


1045: Refreshments and Posters


1115: Dr Marcel Hollenstein, Institut Pasteur, Paris, France

Expansion of the genetic code through the enzymatic construction of artificial metal base pairs


1145: Professor Elena Bichenkova, University of Manchester, Manchester, UK

‘Cleave and leave’catalytic oligonucleotide conjugates for future therapeutic applications


1215: Professor Ken Howard, Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, Denmark

Albumin-based delivery of nucleic acid therapeutics: harnessing nature to cure disease


1245: Dr Emily Linnane, AstraZeneca R&D, IMED Oncology, Cambridge, UK

Building Fundamental Mechanistic Insights into Antisense Oligonucleotide Uptake in Non-Small Cell Lung Cancer


1305: Lunch (provided) and Posters


1400: Dr Mark Edbrooke, AstraZeneca R&D, IMED Oncology, Cambridge, UK

High-affinity antisense oligonucleotides (ASOs) targeting Foxp3 inhibit the immunosuppressive function of regulatory T cells and produce anti-tumour effects in syngeneic tumour models


1430: Dr Linda Poppelwell, Royal Holloway-University of London, London, UK

Combination antisense oligonucleotide treatments for Duchenne muscular dystrophy


1500: Professor Francesco Muntoni, UCL GOS Institute of Child Health, University College London, UK

Splice switching antisense oligonucleotides in neuromuscular disorders


1530: Refreshments and Posters


1600: Professor Peter Zammit, King’s College London, London, UK

Use of antisense oligonucleotide-mediated exon-skipping to remove a LMNA exon containing a pathogenic missense mutation causing laminopathy


1630: Dr Sylvain Ladame, Imperial College London, London, UK

Engineered hydrogels for sensing of nucleic acid biomarkers in biofluids: a step toward new diagnostic tests for Cancer


1700: Professor Andrew Miller, Veterinary Research Institute, Hudcova, Brno, Czech Republic, and KP Therapeutics,, Manchester, UK

Designing a future for RNA therapeutics and vaccines with Project FIT


1730: Dr Adrien Weingaertner, Silence Therapeutics GmbH, Berlin, Germany

Development of innovative hepatocyte-targeted siRNA conjugates for the treatment of liver-related disorders.


1800: Discussion and close